NME6

Across TCGA pan-cancer cohorts, NME6 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of NME6’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NME6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NME6 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

BLCA, KIRC, and LIHC are the cancer types where NME6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NME6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	+0.752	<.001	11	view →
KIRC	Female	II,III,IV	−0.649	<.001	11	view →
LIHC	Female	II,III,IV	+1.051	<.001	9	view →
COAD	Female	All	+0.388	<.001	9	view →
BRCA	All	II,III,IV	+0.423	<.001	6	view →
LUAD	All	All	+0.247	<.001	6	view →
STAD	Male	II,III,IV	+0.612	.002	4	view →
THCA	All	II,III,IV	−0.247	.010	4	view →
CHOL	Male	All	+1.420	<.001	3	view →
KIRP	Female	II,III,IV	+0.400	.028	2	view →
UCEC	All	III,IV	+0.366	.048	2	view →
KICH	All	All	−0.379	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

NME6–BLCA

Open the BLCA breakdown →